Return on investment of public health interventions: a systematic review

Rebecca Masters,1,2 Elspeth Anwar,2,3,4 Brendan Collins,2,4 Richard Cookson,5 Simon Capewell2

ABSTRACT
Background Public sector austerity measures in many high-income countries mean that public health budgets are reducing year on year. To help inform the potential impact of these proposed disinvestments in public health, we set out to determine the return on investment (ROI) from a range of existing public health interventions.

Methods We conducted systematic searches on all relevant databases (including MEDLINE; EMBASE; CINAHL; AMED; PubMed, Cochrane and Scopus) to identify studies that calculated a ROI or cost-benefit ratio (CBR) for public health interventions in high-income countries.

Results We identified 2957 titles, and included 52 studies. The median ROI for public health interventions was 14.3 to 1, and median CBR was 8.3. The median ROI for all 29 local public health interventions was 4.1 to 1, and median CBR was 10.3. Even larger benefits were reported in 28 studies analysing nationwide public health interventions; the median ROI was 27.2, and median CBR was 17.5.

Conclusions This systematic review suggests that local and national public health interventions are highly cost-saving. Cuts to public health budgets in high income countries therefore represent a false economy, and are likely to generate billions of pounds of additional costs to health services and the wider economy.

INTRODUCTION
Benjamin Franklin once famously stated that “an ounce of prevention is worth a pound of cure”. Long-term pressures on public sector costs due to demographic and technological changes and cost inflation in the caring professions have intensified following the 2008 global financial crisis. Public health is often considered a politically soft target for budget cuts, as recently demonstrated by major budget reductions in the UK.1–3

The benefits of population-level public health expenditure—unlike those of personal healthcare and social care expenditure—tend to be long term, mostly accruing after the current politicians and policymakers have moved on. Though large and certain at the population level, benefits are also seen as small and uncertain for individual voters. It is therefore important to take a hard look at the cost-effective evidence, and move towards more rational decision-making in this politically charged area.

Return on investment (ROI) and cost-benefit ratio (CBR) are two forms of economic evaluation that value the financial return, or benefits, of an intervention against the total costs of its delivery. The CBR is the benefit divided by the cost, and the ROI is the benefit minus the cost expressed as a proportion of the cost, that is, the CBR−1. To help inform the discussion of proposed cuts to public health budgets, we set out to determine the ROI and opportunity cost for a range of public health interventions at the local and national levels. The theory underpinning this review is that, because political backing for public health intervention is often lacking, many interventions with a high ROI are not funded. This is because public health interventions are often opposed by powerful commercial interests, and the health gains for individuals are often perceived as too small to sway their voting intentions, despite adding up to large gains at the population level.4

METHODS
We conducted a systematic review to examine the ROI of public health interventions delivered in high-income countries with universal healthcare. These included the UK, Western Europe, the USA, Canada, Japan, Australia and New Zealand.

Search strategy
The authors used Acheson’s definition of public health when considering our search strategy: “The science and art of promoting and protecting health and well-being, preventing ill-health and prolonging life through the organised efforts of society”.5 This definition is purposefully broad and the authors felt that it would incorporate the various fields of public health. We searched the PubMed, MEDLINE, Scopus, CINAHL, Cochrane, PsycInfo and AMED databases using the following search terms: ‘public health’ (all fields) AND ‘return on investment’ OR ‘cost benefit analysis’ (title or abstract). We also hand searched the references of the included analyses to identify any further studies. A grey literature search was completed using Google, yielding three additional results. Limits were set to publications in the English language, and to interventions targeted at humans (where applicable). Studies with poor generalisability to the UK were excluded, including a number from the USA that may poorly reflect UK healthcare systems, structure and demographics.

Study selection and inclusion criteria
We included studies of any design that reported a ROI of public health interventions delivered in industrialised countries providing universal healthcare.
Selection of articles and extraction of data
One investigator (RM) performed the initial screening of the titles. A second reviewer (EA) independently reviewed the titles and potentially relevant abstracts. The results were cross-referenced and any disagreements were discussed with a third reviewer (BC).

One investigator (RM) led the data extraction and quality assessment, which was then independently duplicated by EA. A third reviewer (BC) adjudicated on any disagreements regarding result details or quality assessment. RM contacted authors for additional data in three cases, with two responses.

Assessment of methodological quality in included studies
The methodological quality of each included study was assessed independently by two reviewers (RM and EA) using the National Institute for Health and Care Excellence (NICE) quality appraisal checklist for economic evaluations to assess the quality and external validity of each study.6 Disagreements in methodological quality assessments for all the included studies were resolved by consensus or by recourse to a third member of the review team (BC).

RESULTS
We identified 2957 potentially relevant titles, after excluding 2559 duplicates. A further 2816 papers were excluded following title or abstract review. We finally included 32 relevant titles published over four decades (see online supplementary figure S1).

Results were stratified by public health specialty (table 1), and by interventions at a local level (table 2) or national level (table 3). Results were reported in five different currencies, as detailed in tables 2 and 3.

The median ROI for all public health interventions was 14.3, and the median CBR was 8.3.

The reported ROI and CBRs ranged widely. The ROIs ranged from −21.27 (influenza vaccination of healthy workers7) to 221.8 (single measles vaccination8). The CBRs ranged from 0.66 (20 mph zones in low-impact areas9) to 167.5 (range from 0.7 to 221.8). The median CBR was much higher at 14.4 (range 10.3 to 29.4).10

ROI of public health programmes stratified by specialism
Analysis by specialism revealed that health protection and legislative interventions generally yielded high returns on investment, often being delivered on a national basis and only requiring a one-off intervention (such as a vaccination or a new tax). In contrast, interventions for healthcare public health, health promotion or wider determinants typically had lower returns, being often more complex, resource intensive and sustained. Figure 1 provides overviews of the median, maximum and minimum ROI by specialism, and figure 2 provides an overview of the median, maximum and minimum and CBR values stratified by specialism.

Health protection interventions
Eighteen studies reported a large ROI in relation to health protection. The ROI median was 34.2, and ranged from −21.37 to 221.8, and the CBR median was 41.8 (range from 1.211 to 167.10).

Health promotion interventions
Fifteen health promotion interventions were reported, 12 ROI studies and 3 CBR studies. Returns on investment were variable. The median ROI was 2.2 (range 0.712 to 6.213). The median CBR was 5.8 (range 310 to 8.616).

Legislative interventions
Four studies reported on legislative interventions, with substantial returns. The median ROI was 46.5 (range 3815 to 5515). The median CBR was 5.8 (range 310 to 8.6).

Healthcare public health interventions
Six studies reported ROIs in relation to healthcare public health interventions. The ROI median was 5.1, and ranged from 1.117 to 19.315. No studies reported a CBR.

Wider determinants interventions
Twelve studies reported a return on wider determinants interventions (for instance, targeted at children or juvenile offenders). The median ROI was 5.6 (range 1.119 to 10.810) with a median CBR of 7.1 (range 0.66 to 23.6).14

ROI of public health interventions by level
A total of 29 studies reported returns on investment or CBRs in relation to local public health interventions. The median ROI was 4.1, and ranged from −0.922 to 19.318. The median CBR was 10.3 (range −0.727 to 23.619).

There were 28 studies reporting on national public health interventions. The median ROI was 27.2 and ranged from −21.37 to 221.8. The median CBR was 17.5 (range 1.211 to 167.8).

| Table 1 | ROI of public health programmes overall, and stratified by level and specialism |
|------------------------|------------------------|------------------------|------------------------|------------------------|------------------------|
| Overall | 14.3 | −21.3 to 221 | 34 | 8.3 | 0.7 to 29.4 | 23 |
| Local level | 4.1 | 0.9 to 19.3 | 18 | 10.3 | 0.9 to 23.6 | 11 |
| National level | 27.2 | −21.3 to 221 | 17 | 17 | 1.2 to 167.5 | 10 |
| Specialism | | | | | |
| Health protection | 34.2 | 0.7 to 221 | 8 | 41.8 | 1.1 to 167.5 | 10 |
| Legislation | 46.5 | 38 to 55 | 2 | 5.8 | 3 to 8.6 | 2 |
| Health promotion | 2.2 | 0.7 to 6.2 | 12 | 14.4 | 2 to 29.4 | 3 |
| Healthcare public health | 5.1 | 1.1 to 19.3 | 6 | None reported | None reported | None reported |
| Wider determinants | 5.6 | 1.1 to 10.8 | 6 | 7.1 | 0.7 to 23.6 | 6 |

CBR, cost-benefit ratio; ROI, return on investment.
| Reference          | Intervention                                                                 | Population                                                                 | Benefit-cost ratio | Return on investment | Cost perspective       | Discount rate | Time horizon | Study quality |
|--------------------|-------------------------------------------------------------------------------|------------------------------------------------------------------------------|--------------------|----------------------|------------------------|---------------|--------------|---------------|
| Andresen et al     | Supervised injection facilities                                               | IDU population of Vancouver, Canada                                          | 5.12               | $7.50–$19.35         | Medical and societal   | 3%            | Lifetime     | ++            |
| Arrieta et al      | Home blood pressure monitoring for hypertension diagnosis and treatment       | 16 375 participants, USA                                                     |                    | $1–$1.17             | Medical                | None          | 10 years     | ++            |
| Baker et al        | Workplace obesity management                                                  | 890 employees, USA                                                           | 20.6               | $1–$1.17             | Medical and societal   | 8%            | 18 months    | ++            |
| Beard et al        | Community-based falls prevention                                               | 2000 cases and 1600 matched controls, Australia                            |                    | $1–$1.17             | Medical and societal   | None          | 1 year       | –             |
| Collins et al      | Smoking cessation                                                              | Population of Wirral, UK                                                     | 5.04               | $1.77                | Medical                | 3.5%          | 20 years     | ++            |
| Dopp et al         | Multisystematic therapy with serious juvenile offenders and their siblings    | 305 participants, USA                                                        |                    | $2.03                | Medical and societal   | None          | 1 year       | –             |
| Guo et al          | Improved walking and cycling infrastructure                                     | 4674 participants, USA                                                      | 1.87               | $1.78                | Medical                | 3%            | 10 years     | ++            |
| Kleitz et al       | Multisystematic therapy with serious juvenile offenders                        | 176 participants, USA                                                        | 9.51–23.59         | $0.87                | Medical and societal   | 3%            | 1.3 years    | –             |
| Kuehl et al        | Workplace health promotion for fire fighters                                  | 1369 fire fighters, USA                                                      | $4.61              | $2.03                | Medical and insurer    | None          | 7 years      | –             |
| Long et al         | Health promotion programme for hospital staff                                 | 4402 hospital staff, USA                                                    | $2.87              | $2.03                | Employer               | None          | 1–4 years    | +             |
| Moore et al        | Medication management for high-risk groups                                    | 4500 health plan participants, USA                                           | $2                 | $2.03                | Insurer                | None          | 1 year       | –             |
| Medivle et al      | Speed cameras in urban settings                                               | Barcelona, Spain                                                            | $6.80              | $0.87                | Medical and societal   | None          | 2 years      | ++            |
| Nelson et al       | Water fluoridation                                                            | Population of Houston, Texas                                                | $1.51              | $0.87                | Societal               | 10%           | 10 years     | ++            |
| Nyman et al        | Workplace health promotion                                                    | 1757 cases and 3619 matched controls, employer, USA                         | $0.87              | No                   | Societal               | None          | 2 years      | +             |
| Ozminkowski et al  | Workplace health management                                                   | 25 931 Citibank employees                                                   | $4.61              | $2.03                | Medical and insurer    | None          | 3.2 years    | ++            |
| Peters et al       | 20 mph zones in London                                                         | Population of London, UK                                                    | 0.66–2.19          | $10.83               | Medical and societal   | 3.5%          | 10 years     | ++            |
| Reynolds et al     | Intensive early education programme for socioeconomically deprived families   | 1539 participants, USA                                                      | $3.97              | $10.83               | Medical and societal   | None          | 3 years      | ++            |
| Reynolds et al     | Intensive early education programme for socioeconomically deprived families   | 850 participants, USA                                                        | $8.24              | $0.87                | Medical and societal   | None          | 4 years      | ++            |
| Reynolds et al     | Intensive early education programme for socioeconomically deprived families   | 553 participants, USA                                                        | $2–$2.25           | $1.98                | Medical and legal      | None          | 10 and 22 years | ++            |
| Richard et al      | Tobacco cessation                                                             | 805 Medicaid insured tobacco users, USA                                     | $2.84              | $8.24                | Medical and societal   | None          | 4 years      | ++            |
| Rundell et al      | Therapeutic services for alcoholism                                           | 3034 Oklahoma alcohol service users, USA                                    | $1.98              | $0.87                | Medical and legal      | None          | 10 and 22 years | ++            |
| Schwartz et al     | Wellness and disease prevention programme                                      | 57 940 health insurance clients, USA                                         | $2.02              | $2.84                | Medical and societal   | None          | 8 years      | –             |
| Schweinhart et al  | Preschool education programme for socioeconomically deprived children         | 123 preschool children, USA                                                 | $7.16              | $0.87                | Medical and societal   | None          | 3 years      | –             |
| Steinbach et al    | 20 mph zones in London                                                         | Population of London, UK                                                    | £1.12              | $2.84                | Medical               | None          | 10 years     | –             |
| Spence et al       | Outpatient pharmacy services for medication adherence                         | 2957 matched cases and controls, USA                                        | $5.97              | $2.84                | Medical and productivity | None          | 1 year      | –             |
| Van Vorno et al    | Heart failure disease management                                              | 1360 matched cases and controls, USA                                        | $1.15              | $0.87                | Medical and societal   | None          | 1 year       | –             |
| Wang et al         | Bike and pedestrian trails                                                    | 225 351 individual uses of bike and pedestrian trails over a 1 year period, USA | $2.94              | $0.87                | Medical and societal   | None          | 10 years     | –             |
| Windsor et al      | Antinatal stop smoking services                                                | 994 pregnant smokers in Alabama, USA                                        | 6.72–17.18         | $2.94                | Medical               | None          | 5 years      | –             |
| Reference                | Intervention                                                                 | Population     | Benefit-cost ratio | Return on investment | Cost perspective | Discount rate | Time horizon | Study quality |
|--------------------------|-------------------------------------------------------------------------------|----------------|-------------------|----------------------|-----------------|--------------|--------------|---------------|
| Abelson et al 10         | Hib vaccination                                                                | Australia      | 1.06              | Medical              | 5%              | 15 years     | ++           |
| Abelson et al 10         | HIV/AIDS prevention                                                            | Australia      | 4                 | Medical              | 5%              | 25 years     | ++           |
| Abelson et al 10         | Measles vaccination                                                            | Australia      | 167               | Medical              | 5%              | 33 years     | ++           |
| Abelson et al 10         | Programmes to reduce rates of coronary heart disease                          | Australia      | 11                | Medical              | 5%              | 40 years     | ++           |
| Abelson et al 10         | Programmes to reduce tobacco consumption                                       | Australia      | 2                 | Medical              | 5%              | 40 years     | ++           |
| Abelson et al 10         | Road safety campaigns                                                         | Australia      | 3                 | Medical              | 5%              | 40 years     | ++           |
| Boccalini et al 22       | Universal hepatitis B vaccination                                              | Italy          | €2.78             | Medical and societal | 3%              | 20 years     | ++           |
| Bonin et al 58           | Parenting programmes for the prevention of persistent conduct disorders       | England        | 7.89              | Medical and societal | 3.5%            | 35 years     | ++           |
| Drummond 11              | Needle exchange                                                                | Australia      | 1.2               | Public health        | 5%              | Lifetime     | ++           |
| Evans-Lacko et al 12     | Antistigma social marketing campaign                                           | England        | £0.7 to £1.90     | Unclear              | None            | 1 year       | -            |
| Garpenholt et al 38      | Hib vaccination                                                                 | Sweden         | 1.59              | Medical              | 3%              | 20 years     | ++           |
| Gortmaker et al 15       | Sugar sweetened beverage tax                                                   | USA            | $55               | Medical              | 3%              | 10 years     | ++           |
| Gortmaker et al 15       | Eliminating tax subsidy of nutritionally poor food advertising to children     | USA            | $38               | Medical              | 3%              | 10 years     | ++           |
| Gould 8                  | Lead paint control                                                             | USA            | $17 to $221       | Medical and societal | None            | Unclear      | -            |
| Holtgrave et al 34       | HIV counselling, testing, referral and partner notification services          | USA            | 20.09             | Societal             | 6%              | Lifetime     | ++           |
| Hutchinson et al 35      | Expanded HIV testing                                                           | USA            | $1.46 to $2.01    | Health sector        | 3%              | Lifetime     | ++           |
| Kwon et al 16            | Needle exchange                                                                | Australia      | $1A1.3 to $1A5.5  | Health sector        | 3%              | Lifetime     | ++           |
| Lokkerbol et al 16       | Telemedicine for depression                                                    | The Netherlands| £1.45 to £1.76    | Medical              | 1.5% costs, 4% effect | 5 years  | ++           |
| McGuire et al 16         | Family planning services                                                       | UK             | 11.09 to 29.39    | Medical              | 6%              | Lifetime     | ++           |
| Miller et al 36          | Booster seats for 4–7 years olds                                               | USA            | 8.6               | Medical              | 3%              | 3 years      | ++           |
| Nguyen et al 17          | Needle exchange                                                                | USA            | $3.48             | Medical              | None            | 1 year       | +            |
| Nichol et al 17          | Influenza vaccination of healthy workers                                       | USA            | $21.27 to $1A74.32| Societal             | 3%              | 1 year       | +            |
| Romano et al 40          | Folic acid fortification of grain                                               | USA            | 4.3 to 6.1        | Human capital        | 4%              | Lifetime     | ++           |
| Trust for America 13     | Primary and secondary prevention programmes                                    | USA            | $6.2              | Medical              | 0%              | 10–20 years  | +            |
| Wang et al 20            | Universal school nursing services                                              | USA            | $2.20             | Societal             | None            | 1 year       | +            |
| White et al 38           | MMR vaccination                                                                 | USA            | 14                | Medical              | 10%             | Lifetime     | ++           |
| Ding et al 28            | Hospital-based postpartum influenza vaccination                                | USA            | $1.7              | Medical and societal | 3%              | 1 year       | ++           |
| Zhou et al 28            | Hib vaccination                                                                 | USA            | 5.4               | Medical and societal | 3%              | Lifetime     | ++           |

Hib, haemophilus influenzae type b; MMR, measles, mumps and rubella.
DISCUSSION

Our systematic review offers several potentially important observations

First, even with the most rudimentary economic evaluations, it was clear that most public health interventions are substantially cost saving. This confirms our theory that public health interventions generally offer a considerable ROI. Median ROI was generally higher than median CBR in all of our key public health expenditure categories. This was because most studies only report one of these two measures, and studies that report ROI tend to have higher estimates. A direct comparison is possible, by converting between ROI and CBR at the study level using the simple formula ROI = CBR − 1.7

Second, we demonstrated a public health ‘effectiveness hierarchy’. Public health interventions at a local level averaged an impressive ROI of 4, meaning that every pound invested yields a return of £4 plus the original investment back. However, ‘upstream’ interventions delivered on a national scale generally achieve even greater returns on investment, particularly legislation (a 10-fold higher ROI averaging 46).

Third, Benjamin Franklin’s belief that “an ounce of prevention is worth a pound of cure” is thus borne out by the costs-savings demonstrated, particularly when compared with recent returns for investment in healthcare.23 It has been estimated that investing an additional £13 000 in the English National Health Service (NHS) can achieve health benefits of one additional quality-adjusted life year (QALY).23 When this health benefit is valued in monetary terms at the UK Department of Health’s current rate of £60 000 per QALY,24 this represents a ROI of 3.16 (£60 000 − £13 000/£13 000).

Fourth, this systematic review was partly prompted by recent government cuts to public health budgets in England. We therefore focused on public health interventions delivered in other high-income countries in order to maximise UK relevance. We can therefore now better estimate the likely opportunity costs of the proposed cuts in local and national public health budgets. The median ROI for all public health interventions was 14.3, and the median CBR was 8.3. An ROI of 14.3 implying a cash return of 1430% would sound too good to be true in the financial world. However, public health is different, because decision-
making is governed by politics rather than markets. Our systematic review clearly demonstrates that there are big public health investment opportunities out there—they just need some political will to implement them. If we take the lower, conservative CBR figure of 8.3, this would suggest that the opportunity cost of the recent £200 million cuts to public health funding in England is likely to be eightfold higher, in the region of £1.6 billion. The UK government’s ‘efficiency savings’ thus represent a false economy which will generate many billions of additional future costs to the ailing NHS and wider UK economy. The recent UK increases in (avoidable) teen pregnancies, sexually transmitted infections, homelessness and suicides are thus predictable and worrying. Do they represent harbinger of worse to come? Although this study draws on the experience of the UK public health system, there are implications for public health systems outside of the UK, which may be guided towards areas of potential underinvestment, and avoid harmful cuts in public health budgets.

**Previous reviews**

Ours may be the first comprehensive systematic review of ROI and CBR to include the broad spectrum of public health interventions. Furthermore, it extends and strengthens earlier, narrower reviews which consistently highlighted the cost-effectiveness of selected public health interventions. These included the Australian Assessing Cost Effectiveness (ACE) Prevention Study and the Health England Leading Priorities (HELP) Tool, which ranked several public health interventions against a set of criteria. NICE appraises and recommends public health programmes and interventions in England. In 2012, they reviewed 200 cost-effectiveness estimates used in their guidance. Many interventions (particularly around smoking cessation) produced a net cost-saving for the NHS, that is, the intervention was more effective and cheaper than the comparator. Most interventions were highly cost-effective with a very low cost per QALY: 85% were cost-effective at a threshold of £20 000 per QALY, and 89% at the higher £30 000 threshold, 5% exceeded £30 000 per QALY and only the final 5% were dominated (ie, more costly and less effective than the comparator).

**Health protection interventions**

Eighteen studies reported ROI or CBR figures in relation to health protection interventions. The median ROI for health protection interventions was very high at 34.2. The Australian single measles vaccination programme in the 1980s and 1990s reported the highest CBR, with a CBR of 167:1. The UK now uses the combined Measles, Mumps and Rubella vaccination that has an excellent ROI of 14:1.

Seven studies assessed the prevention, notification, follow-up and treatment of infectious diseases such as hepatitis B and HIV. Overall, they demonstrated a consistently high ROI, reflecting the high disease burden of infectious diseases and the huge benefits of prevention.

Calculating the ROI of influenza vaccination of healthy working adults is challenging, as it is highly sensitive to the efficacy of the seasonal vaccine. Thus, most such studies have reported a modest twofold ROI overall, but with extreme ROI values ranging from −21 to +174.

**Legislative interventions**

One paper reported ROI in relation to legislative interventions, which offered substantial returns on investment, with a median ROI of 46.5. Furthermore, they are relatively low cost and target behaviour at a national level. Introducing a sugar sweetened beverage tax could save $55 for every single dollar invested in the USA.

**Health promotion interventions**

The 15 studies analysing health promotion interventions reported an overall twofold ROI with a more impressive median CBR of 14.4. Interventions aimed at reducing rates of falls are able to show one of the swiftest returns on investment of any of the public health interventions identified within this study, with a CBR of 20.6 returned within 18 months. Falls prevention interventions by their nature are relatively low cost (structured exercise programmes for those at risk of falls), and yet their potential impact on demand management for hospital services is clearly demonstrated. Shifting investment from secondary care for the treatment of falls to primary prevention would show significant and swift returns on investment.

**Tobacco control interventions** overall reported a twofold ROIs, which increased when targeted at high-risk clients such as pregnant women. Such contrasting results perhaps highlight the complexity of public health interventions.

**Healthcare public health interventions**

Six studies reported healthcare public health results, offering a substantial median ROI of 5.14. The majority focused on disease management or medication adherence for high-risk patients, such as home blood pressure monitoring for hypertension diagnosis and treatment.

**Wider determinants interventions**

Twelve studies reported results for wider determinants interventions. Public health interventions addressing wider determinants also averaged a fivefold ROI. Several studies assessed effectiveness of early years interventions, particularly those targeted at juvenile offenders, or those deemed to be at risk of future offending. Although much of this literature is from the USA, emerging UK evidence demonstrates similar returns to society and the wider economy. The benefits of early years interventions thus extend far beyond health, with participants reporting improvements in literacy, job prospects and earnings (hence savings to the criminal justice system, increased taxation of higher earnings, etc).

This also highlights the ‘cross-sector flow problem’: cost-effective public health programmes may not be commissioned if decision-makers are only looking through a narrow health lens.

**STRENGTHS**

We describe a carefully conducted systematic review. Although the precision of application of ROI calculations varies widely, even the most rudimentary analyses consistently suggest that most public health interventions are substantially cost-saving.

**LIMITATIONS**

Several limitations should be considered. First, the difficulty of defining what constitutes a ‘public health intervention’, particularly those focused on wider determinants. We purposefully cast the net wide to achieve a broad systematic review. Further analysis of particular topic areas might now be beneficial.

Second, publication bias appears likely, and even some published studies may have been missed. Such studies are inevitably scattered across a wide field of journals and some economic studies may only be available via organisational websites. However, we did search the grey literature and we did identify almost 3000 total studies—a reassuringly high number.

Third, we did not conduct a formal meta-analysis because of the very inconsistent manner in which ROI was calculated, with differing cost perspectives, time horizons and discount rates. Discount rates
ranged from 0% to 10%. A high discount rate disadvantages public health interventions that have a long payback time. Conversely, a 1 year time horizon may offer too short a time frame.

Fourth, the generalisability of the interventions conducted from one country to the next will vary. Participants in US studies may poorly reflect UK demographics and vice versa. Furthermore, some studies focused on vaccination practices that are no longer employed in a number of countries (eg, single measles and haemophilus influenzae type b vaccinations). Similarly, the majority of workplace health promotion initiatives come from the USA, where employers who pay for employees’ healthcare will have an additional financial incentive to promote the health of their workforce.

Fifth, the quality of the economic evaluations varied considerably. Practice has clearly improved substantially since the 1970s, with recent evaluations employing more sophisticated modelling techniques. Designing such studies can be challenging as public health interventions are often complex and multifactorial, and it can be difficult to isolate an effect size even within a randomised controlled trial. Some of the published literature may therefore systematically overestimate or underestimate the ROI of interventions, and hence the need for more research.

Unanswered questions and future research

There is a clear need for further high-quality economic evaluations of public health interventions, which include a range of discount rates and robust sensitivity analyses.

Implications for clinicians and policymakers

Overall, the results of our systematic review clearly demonstrate that public health interventions are cost-saving, both to health services as well as the wider economy. Furthermore, some are very rapid: falls prevention interventions reported substantial returns within 6–12 months. One might reasonably expect equally rapid returns for preventive interventions such as immunisation, healthcare, smoking cessation and nutrition. Although attempting to quantify returns within a short timescale can be challenging, even larger returns on investment were seen over a 10–20 years time horizon. This has significant implications for policymakers, who often work to a much shorter time horizon (typically 3–5 years). We suggest that Public Health England, NICE and other advisory bodies therefore need to routinely emphasise that public health interventions can offer surprisingly rapid returns, which may increase further over the longer term.

CONCLUSIONS

This systematic review suggests that local public health interventions are cost-saving, and offer substantial returns on investment, nationwide programmes even more so. The cuts to public health budgets therefore represent a false economy. They are likely to generate billions of pounds of additional costs to the health services and wider economy.

What this study adds

This systematic review demonstrates a median return on investment of public health interventions of ∼14.1. Thus, for every £1 invested in public health, £14 will subsequently be returned to the wider health and social care economy. Furthermore, this review categorises the return on investment according to the public health specialty and local versus national levels of intervention. It suggests that cuts to public health services are short sighted and represent a false economy, with substantial opportunity costs.

REFERENCES

1 British Medical Association. Local authorities plunder ring fenced public health funds. 2015. (cited 15 October 2015). http://www.bma.org.uk/news-views-analysis/news/2015/01/local-authorities-plunder-ringed-public-health-funds
2 The Kings Fund. Cuts to public health spending: the falsest of false economies. 2015 (cited 12 February 2016). http://www.kingsfund.org.uk/blog/2015/08/cuts-public-health-spending-falsestfalse-economies
3 British Medical Journal. Raiding the public health budget. 2014. (cited October 2015). http://www.bmj.com/content/348/bmj.g2274
4 Hauck K, Smith P. Public choice analysis of public health priority setting. In: Cuyer A, ed. Encyclopaedia of health economics. Oxford, UK: Elsevier, 2014:184–93
5 Faculty of Public Health. What is Public Health [internet]. (cited 20 Jan 2017). http://www.fph.org.uk/what_is_public_health
6 National Institute for Clinical Excellence. Methods for the development of NICE public health guidance (third edition). Appendix I Quality appraisal checklist—economic evaluations. 2012. (cited 2 December 2015). https://www.nice.org.uk/article/pmg41/chapter/Appendix-I-Quality-appraisalchecklist-economic-evaluations
7 Nichol KL. Cost-benefit analysis of a strategy to vaccinate healthy working adults against influenza. Arch Intern Med 2001;161:749.
8 Gould E. Childhood lead poisoning: conservative estimates of the social and economic benefits of lead hazard control. Environ Health Perspect 2009;117:1162–7.
9 Peters JL, Anderson R. The cost-effectiveness of mandatory 20mph zones for the prevention of injuries. J Public Health (Oxf) 2013;35:40–8.
10 Abelson P, Taylor R, Bulter J, et al. Returns on investment in Public Health. Canberra: Department of Health and Ageing, 2003.
11 Drummond M. Return on investment in needle and syringe programs in Australia: a summary report for the Commonwealth Department of Health and Ageing. Perth: Commonwealth of Australia, 2002.
